HALO 250516 55.00P(HALO250516P55000) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

HALO250516P55000

Watchlist

0.55
0.000.00%

15min DelayClose May 2 16:00 ET

0.60High0.50Low

Intraday

5D
Daily

News

Earnings Preview: HALO to Report Financial Results Post-market on May 06
Moomoo NewsApr 30 21:00 ET
Alnylam, Halozyme Among Latest Firms to Win EU Backing for Drugs
Seeking AlphaApr 28 12:04 ET
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation
MT NewswiresApr 28 11:41 ET
Halozyme to Report First Quarter 2025 Financial and Operating Results
PR NewswireApr 28 08:30 ET
Express News | Halozyme Announces argenx Received Positive Chmp Opinion for Vyvgart® (Efgartigimod Alfa) Subcutaneous Injection With Enhanze® for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
ReutersApr 28 07:30 ET
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $72
Moomoo NewsApr 26 03:33 ET · Ratings

Comments

Teddy123

Apr 11 15:27

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating

$Halozyme Therapeutics (HALO.US)$
Game-Changing FDA Approval: New Self-Injectable Treatment Transforms Rare Disease Care

Teddy123

Apr 9 20:46

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

$Halozyme Therapeutics (HALO.US)$ is
Major EU Approval: Revolutionary Subcutaneous Multiple Myeloma Treatment Gets Green Light

Teddy123

Apr 7 21:53

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

$Halozyme Therapeutics (HALO.US)$
Major EU Victory: Halozyme's ENHANZE Tech Gets Green Light for Advanced Lung Cancer

Noah Khos

Feb 18 06:42

$Halozyme Therapeutics (HALO.US)$ potential $60 post earnings report on 18th

Meltyy

May 22, 2024 15:41

Clinical Updates💉
⇒ $Larimar Therapeutics (LRMR.US)$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals (CTXR.US)$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics (HALO.US)$ $Bristol-Myers Squibb (BMY.US)$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...